The Planning and Evaluation functions of the University of Colorado Cancer Center (UCCC) are conducted by groups of external and internal advisors who provide critical input and advice, both formal and informal, in the development of the programs and capabilities of the Cancer Center. The advice provided by these groups, along with the individual insight and information provided by UCCC leadership and other individuals and organizations, provides the substance from which the UCCC Strategic Plan is developed, implemented, evaluated, and revised. External advisory groups include the External Advisory Board (EAB), whose members include nationally recognized scientific experts in areas of cancer research of particular relevance to the research programs and shared resources of the UCCC as well as five Directors of NCI designated Cancer Centers. The Community Advisory Board (CAB) comprises business, community, and philanthropic leaders within the Denver region who are committed to the advancement of the center and play a major fundraising role. Other external advisory groups include specific EAB's for our Lung SPORE and developing large applications and individual consultants to provide advice and guidance on specific, strategic initiatives of the UCCC. Internal advisory groups engaged in planning and evaluation include the Internal Advisory Board (lAB), comprising both clinical and basic science department chairs or their representatives who meet quarterly with UCCC leadership. The Consortium Advisory Committee includes representatives from every UCCC consortium institution and assists in the development, implementation and evaluation of research initiatives of value to the UCCC consortium. Playing a principal role in internal planning and evaluation functions is the biweekly Executive Committee, consisting of the Director, Deputy Director, Senior Associate Director (AD) for Translational and Collaborative Research, and the AD's for Cancer Prevention and Control Clinical Services and Administration and Finance. Complementing the Executive Committee is the Governance Committee, convening monthly and comprising the Director, Deputy Director, all Associate Directors, Program Leaders and Shared Resource Directors. A number of Operational Committees provide input and evaluation to UCCC leadership on areas such as membership, protocol review and monitoring, clinical services, shared resource management, education, and seed grants. Other critical sources for planning and evaluation input are our center-wide and program retreats, seminar series, and symposia.

Public Health Relevance

NCl-designated Cancer Centers are the centerpiece of the national effort to reduce morbidity and mortality from cancer. As an NCl-designated Comprehensive Cancer Center, the University of Colorado Cancer Center (UCCC) is dedicated to the mission of developing more effective approaches to prevention, diagnosis, and therapy. Planning and Evaluation efforts of the UCCC provide the means through which strategic decision-making and subsequent implementation are conducted to accomplish the UCCC mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-24
Application #
8465397
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-06
Project End
2017-01-31
Budget Start
2012-08-06
Budget End
2013-01-31
Support Year
24
Fiscal Year
2012
Total Cost
$15,955
Indirect Cost
$5,415
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Harder, Bryan; Tian, Wang; La Clair, James J et al. (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56:1493-1500
Chen, Yufei; Anastassiadis, Konstantinos; Kranz, Andrea et al. (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell 31:755-770.e6
DeRyckere, Deborah; Lee-Sherick, Alisa B; Huey, Madeline G et al. (2017) UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res 23:1481-1492
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Neelakantan, Deepika; Zhou, Hengbo; Oliphant, Michael U J et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun 8:15773
Barón, Anna E; Kako, Severine; Feser, William J et al. (2017) Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol 12:1512-1523
Todd, Maria C; Langan, Thomas A; Sclafani, Robert A (2017) Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. J Cancer 8:190-198
Brown, Dustin G; Borresen, Erica C; Brown, Regina J et al. (2017) Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr 117:1244-1256
Haverkos, Bradley M; Abbott, Diana; Hamadani, Mehdi et al. (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221-228
Shearn, Colin T; Saba, Laura M; Roede, James R et al. (2017) Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. Free Radic Biol Med 113:280-290

Showing the most recent 10 out of 1448 publications